Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Meisl T, Pinter G, Dieplinger H
Institute of Medical Biology and Human Genetics, University of Innsbruck, Austria.
Thromb Haemost. 1995 Oct;74(4):1025-8.
Recent studies have indicated controversial effects of low molecular weight heparin (LMWH) on lipid metabolism in patients on chronic hemodialysis as compared to unfractionated heparin (UFH). We therefore conducted a cross-sectional multicentre study comparing 153 patients treated with LMWH and 153 patients with UFH, matched for sex, age and diabetes mellitus. Both groups have been treated with LMWH or UFH for six months or longer (14.9 vs. 23.4 months). We observed no differences between the UFH and LMWH treatment groups for total cholesterol, LDL cholesterol, triglycerides, apoB, apoA-IV or Lp(a). The only significant differences were seen for HDL cholesterol and the corresponding apolipoprotein apoA-I, which were significantly higher in the UFH group (HDL cholesterol: 0.97 +/- 0.35 mM/l vs. 0.87 +/- 0.37 mM/l, p < 0.05; apoA-I 1.23 +/- 0.27 g/l vs. 1.15 +/- 0.27 g/l, p < 0.05). We conclude that the results of studies investigating the influence of LMWH on lipid metabolism are as heterogeneous as the substances themselves. This challenges the beneficial influence supposedly had by LMWH preparations on lipid metabolism.
最近的研究表明,与普通肝素(UFH)相比,低分子量肝素(LMWH)对慢性血液透析患者的脂质代谢有争议性影响。因此,我们进行了一项横断面多中心研究,比较了153例接受LMWH治疗的患者和153例接受UFH治疗的患者,两组在性别、年龄和糖尿病方面相匹配。两组均接受LMWH或UFH治疗6个月或更长时间(分别为14.9个月和23.4个月)。我们观察到UFH治疗组和LMWH治疗组在总胆固醇、低密度脂蛋白胆固醇、甘油三酯、载脂蛋白B、载脂蛋白A-IV或脂蛋白(a)方面没有差异。唯一显著的差异在于高密度脂蛋白胆固醇及其相应的载脂蛋白A-I,UFH组显著更高(高密度脂蛋白胆固醇:0.97±0.35 mM/l对0.87±0.37 mM/l,p<0.05;载脂蛋白A-I 1.23±0.27 g/l对1.15±0.27 g/l,p<0.05)。我们得出结论,研究LMWH对脂质代谢影响的研究结果与这些物质本身一样具有异质性。这对LMWH制剂对脂质代谢的假定有益影响提出了挑战。